Australian Clinical Labs Limited (ACL) Earnings Call Transcript & Summary
August 17, 2026
Earnings Call Speaker Segments
Joe Geran
executiveRegarding the land where we gather today. I'm speaking to you from Brisbane, on Turrbal, Yuggera, and Jagera country. We recognize the traditional custodians of country across Australia, and the places from which participants are joining this webinar, along with their ties to land, sea, and community. We honor their elders, past and present, and we extend that respect to Aboriginal and Torres Strait Islander peoples present here today. Welcome to the investor webinar covering Australian Clinical Labs' full year financial results. I'm Joe Geran, National Marketing Director at ACL. Joining me on this webinar today are our Group CEO and Executive Director, Melinda McGrath, our incoming Group CEO, Greg Horan, and our CFO, Matt Cordingley. This webinar will last approximately one hour and is being recorded. After the event, a copy of the recording will be posted on ACL's website. By attending, you consent to taking part in the recording. Should you want further details, our privacy policy is available on the website. During this webinar, you'll hear presentations from Melinda, Greg, and Matt, and afterward we'll have time for Q&A.
Joe Geran
executiveIf you'd like to ask something, feel free to raise your hand so you can pose your question live during the webinar. Alternatively, if you'd rather send a written question, which I'll then read aloud, just type it into the Q&A feature you'll find at the bottom of your screen. When we get to Q&A, we'll concentrate on the questions asked most often, and we'll aim to cover as many of them as we can within the time we have. I'd now like to pass things over to our Group CEO, Melinda McGrath.
Melinda McGrath
executiveThanks, Joe. Moving to slide four. Thanks, Joe. Good morning, everyone, and welcome to the presentation of our results for the full year of FY 2026. What we're presenting today once more demonstrates better underlying margins delivered despite considerable industry transformation, unforeseen inflationary expenses, and soft market volume. In this context, we lifted our EBIT and margin past the upper bound of guidance, raised our return on invested capital and our earnings per share, and returned AUD 47 million to shareholders through dividends and share buybacks. In late 2025, anticipating patient fee cuts brought in by the federal government starting in July 2026, we restructured how we operate. Above all, we sought greater command over our own future, and in that effort we launched a number of projects that have delivered benefits during this financial year and that support our outlook. We've achieved earnings growth in a pathology market with unprecedented low growth since the pandemic, one that has included substantial fee cuts. The Australian Clinical Labs team's adaptability and capacity to innovate at every level come through in these results, supported by our strategic initiatives, our resilience, and our flexible business design. We've answered the tough external conditions by optimizing our collection center portfolio, concentrating on profitable contract management, and on the operational side, we've felt the favorable effect of our AI and automation projects on digitizing our billing practice and certain back-end functions.
Melinda McGrath
executiveWhat matters here is that we've built our systems so that better billing is possible going forward. As volumes come back, the redesigned footprint is going to let us gain leverage. The Lab of the Future is coming along nicely and is going to sharpen further how efficient our labs and logistics are, and all the effort we've put into billing is going to give us more levers for price control on tests that Medicare doesn't reimburse. What these results demonstrate is a run rate from business redesign work that is going to offset industry headwinds in this year and help margins improve as we move into 2028. The progress we've made gives us a solid base for earnings growth that lasts, and that will be strengthened once volumes pick up toward the long-term average. Revenue came in at AUD 736 million, which is lower than the same period a year earlier in our low-growth market. Underlying EBIT stands at AUD 69.2 million, a 9.4% margin, and that's 1.7% higher than 2025. As in earlier years, note that we see a skew between the first half and the second half. Margin in the second half was 11%, consistent with the guidance we gave. Underlying NPAT reached AUD 35.5 million, 4.3% above financial year 2025, with underlying earnings per share of AUD 0.183, which is 8.5% higher than financial year 2025. Reported NPAT was AUD 24 million, and Matt is going to walk through why the variance occurred.
Melinda McGrath
executiveThe dividend per share we announced today is AUD 0.0925, bringing the total for the full year to AUD 0.13 per share — a yield of 5.5% and a payout ratio of 69%. Free cash flow came in at AUD 64.7 million, which is down versus financial year 2025, and Matt will speak to that as well. Return on invested capital stands at 25.2%, up from financial year 2025. That figure is also in line with prior years and sits above the 75th percentile of the ASX 300. Capital returns totaled AUD 47 million, roughly equivalent to 10.7% of current market CapEx. Given our strong balance sheet and confidence in our strategy, we will keep buying back shares into 2027. Our core strategy is still centered on generating margin-accretive top-line growth via disciplined network and contract expansion, investment in strategic new business — including non-Medicare-funded pathology and adjacencies — and implementation of revenue and billing enhancements aimed at recovering fees for tests that are currently provided for free. We are also pursuing growth in specialized diagnostics. On top of that, we will keep investing in and applying innovation across our operations. Slide five. Thanks, Joe. This slide lays out the major components behind performance in this financial year, giving insight into how our responses to the external environment have had an impact.
Melinda McGrath
executiveDuring 2026, our revenue took a hit from substantial Medicare reductions affecting vitamin B12 and urine testing, along with a weak GP consultation market. On top of that, respiratory and HPV testing saw a considerable market-wide decline. Lower attendance at GP practices has driven slow GP-referred market volumes, even though yield per attendance has risen relative to earlier periods. Revenue-wise, this has been the biggest impact. As with any business, not every growth line or service and product line turns a profit. We restructured our collection center and contracts portfolio so that we concentrate on profitable revenue. Once fee cuts came in, portions of our network stopped being profitable, and where we couldn't negotiate improved terms, we exited. Some regional labs and collection centers were also closed. Revenue fell in the short term as a result, yet overall EBIT and margin went up. I'm happy to report that in 2027 we have a robust pipeline of new ACCs structured as more suitable arrangements. Beyond that, certain public hospitals in Victoria are insourcing their pathology under government direction. Partial indexation offset the fee cut for active B12 and other testing to a minor extent, and we've recovered most of that through our other activities, upfront patient billing among them.
Melinda McGrath
executiveIn our case, that shortfall—counting the benefit from indexation—came to roughly AUD 14 million in EBIT impact. Had we avoided these adjustments, growth would have come in stronger, though earnings would have been weaker. Turning now to costs: the result incorporates the initial AUD 1.8 million expense tied to the Fair Work Commission ruling on gender undervaluation. Then there are the yearly inflationary effects on labor costs, where the Fair Work Commission lifted wages under modern awards by 3.5%, along with the 0.5% superannuation increase effective 1 July 2025. As you can see, the labor efficiency measures we've implemented have more than compensated for these cost pressures. Keep in mind that we held labor at 43.5% of revenue even with the significant revenue effects I just described. We also encountered broader inflationary pressure than usual across our cost base, particularly on rent and other expenses. Those have been handled effectively through our footprint redesign—rent costs stayed steady as a share of revenue even with the softer top line, which produced a better margin. Our operations teams have performed excellently on consumables, both in contract and inventory management, and we anticipate that actions planned for this year will deliver further lasting positive impact.
Melinda McGrath
executiveSo because of that, we feel the company is in a strong position to handle the challenges we're facing this year and to take advantage of any pickup in volumes as they get back to normal levels. Moving to slide six. Thanks, Joe. I'll now walk through a few operational highlights. Beyond our culture of focusing on outcomes, the effort we've put in over multiple years to bring separate systems together onto one operating platform stands as our biggest competitive edge. We're the sole national pathology provider that runs a single laboratory information system, or LIS. Using one system nationwide cuts down on duplication, generates cost savings, improves customer service, and helps best practices spread across the whole country. As we've demonstrated this year, the LIS means we're in a unique position to seize opportunities or tackle challenges thanks to how the business is structurally designed. None of that would be possible without people and a culture that back the swift uptake of best practice and proactive change. The LIS makes possible first-to-market bolt-on technology and ongoing, sustainable improvement, and it has allowed our billing strategy to work effectively and be rolled out nationally. With multiple versions of the lab system, we'd have needed to program and test every one of them — and bear in mind there are thousands of test combinations and algorithms that must align with the billing system, plus a clinical risk attached to any reprogramming work.
Melinda McGrath
executiveGetting the billing project to where it needed to be required over 18 months, and that was with just a single LIS. This slide lays out the growth efforts and the operating efficiency improvements behind the 20 basis point lift in EBIT margin. I'd note that roughly 20% of revenue now comes from non-Medicare sources. That's B2B or B2C. A central strategy has involved gaining cost control across a wider set of pricing points and recouping fees for tests that today we perform at no charge. We've put money into digitalization tied to our LIS, and we're seeing the payoff in the form of access to additional revenue streams. We view that as a genuine source of benefit going forward, and it will give us greater price control. Through the digital upfront billing projects, we can tackle four buckets of activity. Those are health fund contracts along with other related increases, price increases on tests funded by non-Medicare sources and contracted, upfront billing for overseas patients and students, and upfront billing for unfunded tests — specifically, the ones we presently do with no payment, which turn into debtors or write-offs. These aren't the CON tests. They're tests that, because of Medicare restrictors, can't be reimbursed by Medicare. Typically, such restrictors are time-based or based on clinical condition.
Melinda McGrath
executiveBeyond that, we expanded testing in oncology, genomics, and reproductive health, and outpatient specialist referrals have risen by 4%. Looking at costs this year, even with lower revenue and wage inflation pressure, labor still holds up well at 43.5% of revenue. Lab operational efficiency improved by over 10%, and logistics efficiency also went up by 13%. Thanks to GPS route optimization, we drove nearly one million fewer kilometers than the prior year, and short-term fluctuations in petrol prices had no meaningful effect at all. As I noted, we keep rent under good control despite modest volume growth, and we have a pipeline of profitable new ACCs extending into 2027. We also have multiple AI initiatives in progress aimed at strengthening back office and other functions, which will deliver benefits in 2027 and beyond. Our patient NPS score remains industry-leading at +80. All of this has underpinned our financial year 2026 result, supports our 2027 guidance, and gives us additional runway for performance upside in future periods. This marks my final results presentation for Australian Clinical Labs. I have been with the company since its founding in about 2015. Before I hand over to Matt and Greg, I want to thank our pathologists and scientists for their expertise, their advice, and their commitment to quality, and to acknowledge the dedication of our teams across Clinical Labs who care for our patients every day.
Melinda McGrath
executiveThe work they do is inspiring—it helps save and improve lives for tens of thousands of Australians each day. From what I've shared today, you can see that we have a culture of innovative and driven leadership. I want to acknowledge and thank our leaders and teams across our laboratories, collection centers, the courier network, technology functions, and professional services. Their collaboration and relentless focus on improvement keep redefining what best-in-class looks like. As these results show, this leadership aligns with the interests of our doctors, patients, people, and shareholders, and it is a strength we value greatly. We have a very talented and experienced management team that is innovative and strong at execution, who are specialists in what they do. Most of them have been on the ACL journey from the start. Those who have joined since have added extra dimensions and different ways of thinking. In that time, we've acquired and integrated five pathology businesses, made complex technological enhancements to create our competitive advantage, completed an IPO, and managed through the ups and downs of a pandemic and its aftermath. I'd like to thank them and acknowledge their hard work and support. It has been a privilege working with them.
Melinda McGrath
executiveI want to express appreciation to Stephen Roche for the way he has led, and to the Board for the dedication and perspective they have brought. My best wishes go to both them and Greg as they keep expanding the company. I'm also grateful to our shareholders—lots of them have stayed with us from the IPO onward—for the trust they've placed in us. With that, I'll turn things over to you. Thank you, Matt.
Matt Cordingley
executiveThanks, Melinda. I'll begin by describing how the year took shape instead of focusing on the figures themselves. In FY 2026, the top line slipped modestly, and Melinda has already explained the reasons. Even so, underlying net profit after tax rose 4.3%, while earnings per share climbed 8.5%. A pairing like that isn't coincidence. It comes about because, among other things, we made conscious decisions regarding which revenue we were prepared to keep, knowing that would help the bottom line. On revenue, ACL's MBS outlays fell 0.3% against market growth of 1% in FY 2026. Looking at just the second half, though, ACL's MBS outlays were up 0.6%, while the market grew only 0.3%. We highlighted this at our half-year results, when part of the revenue drop stemmed from deliberate management choices. Fee adjustments and fresh terms attached to legacy contracts pushed those contracts under our return thresholds, so we exited them. We likewise stepped away from collection centers that were not generating minimum contribution margin. As Melinda mentioned, some public hospital work was reclaimed by the states, and keeping it would have been our preference.
Matt Cordingley
executiveOnce you take those items out, though, our underlying revenue line was up 1.1% on FY 2025. Again, the revenue we chose to walk away from didn't fit our return profile, and our long-held position is that a strong, sustainable margin together with profitable revenue growth is what creates value for shareholders. Now, as Melinda laid out when walking through the FY 2025 to FY 2026 EBIT bridge, we shouldn't lose sight of the fact that we took in roughly AUD 14 million of net Medicare fee cuts from the B12 and urine tests, partly offset by a small cushion from indexation across around a third of the schedule. We made it back. We also took in the usual annual modern award wage increases plus AUD 1.8 million of general undervaluation costs during the second half. Even so, underlying EBIT grew 1.7%, and that offset came mainly from three areas. First, labor costs, where ongoing vigilance in aligning worked hours with actual volumes was delivered through our automated tools and processes. Second, operational efficiency in our labs. Third, our procurement focus, which has pushed consumable costs down. Now, I want to stress that all of these represent structural changes to the cost base.
Matt Cordingley
executiveThose aren't savings that happen just once. On the other hand, the difference between our statutory or reported EBIT and underlying EBIT is very largely made up of one-offs. The AUD 6.2 million AIC settlement, along with the AUD 4.2 million non-cash prepayment write-back — both of these trace back to the historical Medlab acquisition in 2022, and a full reconciliation appears in the appendix. Moving to slide nine, it's in our cash flow that the quality of these earnings really shows. We turned 119.2% of cash EBITDA into operating cash flow. That's above 100% once again, and it's consistent with our track record. ACL has continually flowed its earnings into cash flow, and 2026 was no exception. Free cash flow of AUD 64.7 million came in lower than last year with the reduction in revenues, but our underlying profit to cash conversion engine remains unchanged. Two things drove the working capital improvement. Firstly, the benefits from the billing digitalization work, where upfront billing of private paying patients means we collect closer to the point of service. Secondly, the unwind of historical Medlab prepayment, which is a one-off. Our billing initiatives are not one-off, though, and they will provide more benefits as they extend further into tests that are not funded by Medicare into FY 2027 and beyond.
Matt Cordingley
executiveMaintenance CapEx remained inside the historical range of AUD 8 million to AUD 10 million. I'd like to draw attention once more to the efficiency improvements Melinda described. There's a 10.4% increase in panels per FTE, along with the investment in AI and automation, and all of that was delivered within that same envelope. This isn't a transformation that demands heavy capital, which explains our market-leading and enviable return on invested capital of 25.2%. Through dividends and buybacks, we gave back AUD 47.1 million to shareholders — roughly 11% of our market capitalization. Debt funded part of that, though we see it as prudent capital management given how the share price has been trading. Our leverage is conservative and we have financial flexibility. Slide 10 shows our balance sheet, and I'll offer some commentary on the capital allocation reasoning behind it. Net debt at year end stood at AUD 37.4 million, equal to 0.5x underlying EBITDA on a pre-AASB 16 cash basis, and that comes after returning AUD 47 million to shareholders this year plus settling the AIC matter. As I said, by any measure we are conservatively geared, well inside our debt covenants, our facilities extend to September 2027, and we aim to renew or refinance them by December this year.
Matt Cordingley
executiveWith that final dividend, total distributions for the year come to AUD 0.13, which works out to a payout ratio a bit below 70% of underlying NPAT — once again sitting at the upper end of the target range the Board has approved. That increase came on top of repurchasing AUD 21.8 million in shares, something we did, as I noted earlier, purely because we identified value in it for our shareholders. Turning to debt, we regard ACL's modest gearing as suitable for the challenging operating conditions we currently face, and we expect those conditions to correct themselves in time. Even so, this leads our capital management policy to prioritize capacity rather than leverage. Once volumes recover, the operating leverage inherent in how the business is designed, together with our single national LIS platform, is considerable, and our flexibility to fund accretive investments will be even greater. To close, in summary, ACL's financial position features high-quality earnings, sustainable margins, strong and repeatable cash flow conversion, and a balance sheet with the flexibility and capacity to fund accretive growth and dividends for our shareholders. I'll now hand over to our new Incoming CEO, Greg.
Greg Horan
executiveThanks, Matt. Good morning, everyone. For anyone I haven't met yet, my name is Greg Horan. I came on board at ACL on 1 June as Incoming Group CEO, and on 31 August I take up the Group CEO position. After 10 years, Melinda is passing on a leading operator in our sector, and she has been extremely generous with her time during the transition, for which I'm grateful. I've worked 25 years in operating roles across a range of industries, but most recently I led Healthscope, where I had responsibility for 43 hospitals, roughly 20,000 staff, and 5,000 visiting medical officers. The dynamics of this industry and its main participants are very familiar to me. Two things really attracted me to ACL. The first is the character of the business. Pathology is essential healthcare. It underpins a very large share of the clinical decisions made in this country, and demand is supported by an aging population and a rise in chronic disease. That demand does not switch off with the economic cycle. The second is the platform. ACL is one of a small number of truly national operators with genuine scale and a strong clinical presence. Across several years, ACL has constructed a single national operating platform supported by a single laboratory information system.
Greg Horan
executiveThat goes beyond being merely an IT matter. As Melinda and Matt have described, it constitutes a structural advantage. It cuts down on duplication, underpins efficiency, permits technology and billing initiatives to be rolled out nationally, and delivers operating leverage to the business as volumes rise. During my first months, I've been out visiting laboratories and collection centers and meeting our people. Two things stand out to me: the clinical capability throughout the business and the pride our teams take in the work. ACL has demonstrated it can navigate a tough market, soak up cost pressure, make disciplined portfolio decisions, and still lift profitability. The opportunity ahead lies in leveraging the platform more deliberately, growing profitable market participation, turning productivity into cash, and continuing to allocate capital with discipline. That is my view of the next chapter: disciplined value creation built on a resilient national platform. Slide 12 sets out our industry outlook, and diagnostics remains structurally important to healthcare. Over time, demand is underpinned by primary care activity, an aging population, chronic disease, and the growing role diagnostics plays in clinical decision-making. The near-term market, though, has been difficult. GP attendances and pathology episodes remain under long-term trend. Yet the pathology yield per GP consult has kept improving, with every visit to a GP producing more diagnostic work than before, which means that when attendances recover, the volume benefit to us will be amplified.
Greg Horan
executiveOn top of that, the GP bulk billing incentive has drawn a lot of take-up since it was widened in November, and that sits alongside wider government steps designed to make primary care easier to reach. I don't want our investment case to depend on the market bouncing back quickly. We're set up to gain as activity picks up, and the plan rests on what ACL can control, service reliability, referrer engagement, disciplined account management, better billing, improved revenue capture, labor productivity, and capital discipline. This slide pulls together both halves of our investment case: operational improvement and disciplined growth. Where revenue is concerned, we aren't chasing volume just to have volume. Our focus is profitable revenue, better billing, private non-funded test recovery where it makes sense, indexation support, disciplined ACC expansion and optimization, and SunDoctor opportunities where pathology synergies and earnings accretion are clear. Operationally, the focus is just as disciplined. We're drawing on the national platform through Lab of the Future, the National Skin Lab, digital workflow, AI, procurement work benefits, and route optimization. These aren't separate ideas. Every one of them uses scale, process discipline, and technology to bring down our cost to serve. The key point is that these levers are largely within our control.
Greg Horan
executiveThe outside landscape is still tough, yet we aren't sitting idle. Through ACL's platform, we're boosting productivity, safeguarding margin, growing profitably, and creating an operating model that scales better. That's the reason we feel confident about margin stability and the longer-term picture. Turning to slide 14, the growth strategy matches what you've seen previously. What shifts under my leadership isn't where we're headed — it's how hard we push execution and how clearly accountability sits behind every pillar. The single laboratory information system serves as the foundation. It lets us build once and deploy nationally. That counts for billing, automation, AI, workflow quality, laboratory productivity, and post-acquisition integration. Instead of walking through the five pillars individually, I view them as four themes, and evidence already supports each one. First is growing only where we earn a return. That's why we exited collection centers and contracts that couldn't be repriced profitably, and why those we're opening now come on better terms. Second is cutting our dependence on a single payer. About a fifth of our revenue now comes from outside Medicare, and the mix is trending the right way.
Greg Horan
executiveRevenue from commercial contracts rose 17%, while genetics and non-MBS were up more than 7%. SunDoctor and the melanoma commercialization effort sit within that same theme. These are adjacencies built on laboratory capability we already possess, not capability we would need to go out and purchase. The third item is getting paid appropriately for the work we already perform. That means digitized billing on the national system, upfront billing for overseas patients, recovering payment for tests Medicare does not fund for a particular patient, and ongoing advocacy around indexation. Not one of those things needs an additional episode to walk through the door. The fourth is leveraging the single platform to remove cost, which we have shown through industry-leading labor productivity and substantial procurement improvements. The Lab of the Future will take on more than half of our routine work with a 20% efficiency gain. The National Skin Lab will run at a 20% lower cost per case. The row along the bottom is where I would direct your attention. Each pillar carries an outcome we will be measured against: margin, revenue diversification, scale and synergies, revenue quality, and cost per test. Turning to slide 16, this brings me to our FY 2027 guidance. The business has a track record of delivering through significant headwinds, and the FY 2026 result is further evidence of that.
Greg Horan
executiveWhat I want is for the market to keep seeing proof that we deliver. That calls for growth with discipline, execution we're accountable for, and a sustained emphasis on the quality of earnings, on generating cash, and on how we allocate capital. The guidance captures a measured read on the market and a disciplined view of the things within our control. Our targets are revenue between AUD 745 million and AUD 765 million, underlying EBIT of AUD 67 million to AUD 73 million, and an implied EBIT margin of 9% to 9.5%. This range doesn't bake in a fast market recovery. What it does reflect is modest expected market growth, ongoing wage pressure, and the effect of non-industry funding settings — with the exception of the final stage of gender undervaluation for pathology collectors. Once that work is finished, we'll set out the impact at the FY 2027 interim result. It also captures the gains from initiatives already underway: upfront episode billing, price increases on non-MBS funded tests, Lab of the Future, AI initiatives, and aligning our workforce to activity. Share buybacks stay part of the strategy, subject to ongoing review of funding requirements, strategic investments, and same business capital expenditure. The FY 2027 message is clear. We're holding margins stable through known headwinds, we're continuing to execute on initiatives we control, and we're pursuing sustainable growth drivers.
Greg Horan
executiveWith that, I'll turn things back over to Joe.
Joe Geran
executiveThanks, Greg. At this point we’ve got quite a few folks who’ve raised their hands wanting to ask questions. I’ll begin with Andrew Goodsall. Andrew, your line is unmuted. Go ahead whenever you’re ready.
Analyst
analystThanks a lot — and congratulations on your retirement, Melinda, plus a warm welcome to you, Greg.
Greg Horan
executiveMuch appreciated.
Analyst
analystRegarding the Fair Work Commission wage effect, I take it you still won’t clarify health worker qualifications assessments at this point, I suppose. I just want to confirm that we’re still thinking—sorry—phlebotomist pay increases for the full year would be around five? I believe that was what was discussed last time.
Greg Horan
executiveWell, essentially we got that wrong. The figure is roughly 2 higher.
Joe Geran
executiveYeah. It's sort of—
Matt Cordingley
executiveWould you like to handle that one, Melinda? There's some background noise coming through.
Melinda McGrath
executiveYeah. Sorry about that, Joe — I believe your audio is coming through on our end.
Joe Geran
executiveYes, I'm certain, even if the mic stays as it is.
Melinda McGrath
executiveSomeone appears to have their line open. The audio is coming through poorly. All right. My apologies, Matt. Would you like to proceed?
Matt Cordingley
executiveYeah, I believe Andrew's dealing room has a little background noise going on. But regardless.
Melinda McGrath
executiveOh.
Matt Cordingley
executiveYes, Andrew, the AUD 5 million impact for the phlebotomists is correct. That's right. It is built into guidance. We noted that a further, more modest rise will also take effect on 1st of January, when Fair Work updates its rate card. That doesn't apply to every phlebotomist. It hinges on what they were actually paid and on the size of that increase, but it will be smaller than that impact. We would be, yes, we will be working to offset it within the half, the guidance range we gave.
Analyst
analystJust a quick question on a couple of other things. You brought up a buyback. Is there any more detail you can offer on that — when you might begin, how big it could be, anything along those lines?
Matt Cordingley
executiveNot right now, Andrew. Once we reach results, we'll talk with investors. A great deal has shifted when it comes to tax legislation and similar matters. We have considerable flexibility. Some projects are underway this year — Lab of the Future and the consolidated Skin Lab project. Any buyback will depend on other investment priorities for the business, though we'll likely have more to say about that down the line.
Analyst
analystAnd then last thing on co-pay and self-funded and so on. You've clearly discussed that at length. I'm just trying to get a sense of where things stand on that path. Are you only just beginning? Is it more that, I mean, where is the consumer sort of hitting a limit, in your view, or could we—
Melinda McGrath
executiveApologies, Andrew. I'm not sure I followed that correctly. Were you referring to the billing project?
Analyst
analystYes, that's correct.
Melinda McGrath
executiveSo what kind of upside are we talking about? What sort of upside is there?
Analyst
analystSo, where exactly are we in this process?
Melinda McGrath
executiveYeah, no, this is something we're genuinely excited about. It was a tough project, you know, since we actually had to program the lab information system from the customer side. We also had to look up the Medicare system, and the billing at the back end had to match it too, and we've cracked it. There's some in this year, though not that much, and we see it becoming a recurring benefit in the years ahead that we're really excited about. The patient walkout rate when we give them informed consent is very low. We're targeting high volume tests, so it flows through to the bottom line. Obviously we'll be able to put some kind of price increase on those tests, so we'll get benefit into future years. It's quite an untapped opportunity for the business, and we've got the system set up now, and we see further upside into future years. Greg might want to comment a bit on that.
Greg Horan
executiveYeah, no, look, I fully see eye to eye with Melinda on this. The billing initiatives have me genuinely enthusiastic, and they’ll keep delivering compounding returns down the road, and I think Melinda really nailed that point.
Analyst
analystMuch appreciated.
Joe Geran
executiveOkay, moving on, Sacha Krien from E&P is up next.
Sacha Krien
analystMorning, everyone. Congratulations, Melinda. Hi there, Matt and Greg. So, I suppose I'll start with my first question — I'd just really like to get a clear picture of the MBS growth assumption that underlies the 1%-4% revenue growth guidance you've given for FY 2027?
Melinda McGrath
executiveSure, Matt can take that first.
Matt Cordingley
executiveAbsolutely, Melinda. As you're aware, Sacha, our MBS growth has been fairly modest throughout 2026. I mentioned earlier that during the second half our growth ran ahead of MBS outlays, so we did pick up some benefit, or some upside, as the year drew to a close. We're expecting it to be broadly consistent with 2026. That said, we're certainly hopeful it lands toward the upper end of the range, with volume and GP attendances beginning to rise. However, I won't attach a specific figure to that.
Sacha Krien
analystYeah, and does the vitamin B12 change that came in July 2026 give you somewhat of a lift as it cycles through?
Matt Cordingley
executiveAbsolutely. That’s something we’re going to secure a portion of.
Sacha Krien
analystYeah. Turning to the non-Medicare part of your revenue, I'm curious whether you could comment on how well you're able to keep raising prices there. I realize you've described that as being at an early stage. How has demand elasticity played out when it comes to either rolling out upfront billing or putting prices up?
Melinda McGrath
executiveOh, I’ll take that one, Sacha. We’re keenly aware of it. The last thing we want is to hurt ourselves, so we aren’t charging indiscriminately. We’re being very deliberate about where we aim, running pilots, tracking walk-ins and patient walkouts, gauging price elasticity, and tweaking the programs whenever we notice any negative effect. But the walkout rates are, I believe, roughly 8%, which is pretty low. Those individuals wouldn’t have paid in any case. Their test would have been done at no charge, and then they wouldn’t have paid us, so we’re not concerned. Nor will they get funded at a competitor nearby. And we’re starting with high-volume tests, so the benefit is quite good. Naturally, that will flow through to the bottom line. It’s a highly targeted program, but since the business handles such a large volume of the most common tests, the impact is solid. And as I mentioned, that will carry into the future, so it will have a compounding effect.
Sacha Krien
analystAlright, one last quick question if I may, and this one’s for Matt. I just wanted to get some clarity regarding labor cost growth as we move into FY 2027. You reiterated the 4.8 for pathology collectors, and there’s a modest increase arriving in January. Could you give us any kind of parameters around that? And then second, if possible, some indication of what you’re factoring in for health professionals in FY 2027?
Matt Cordingley
executiveOkay, Matt, I’ll address the last part of your question first. When you combine the effect of collectors and health professionals—specifically the impact of gender-based under-valuations—it comes to roughly AUD 7 million in FY 2027. That covers health professionals and collectors, or the initial stage of collectors. Sacha, Fair Work has not yet released a second rate card; it is due to come out on the 1st of January, and that is the reason I’m holding back from giving you a figure. Obviously, we have examined it. Our view is that it is quite modest, and we believe we can offset it within the guidance range we have provided.
Sacha Krien
analystYeah, got it. All right, that's useful. Thanks.
Joe Geran
executiveAppreciate that, Sacha. Moving on, Shane Ponraj joins us from Macquarie. Shane, are you able to hear us?
Melinda McGrath
executiveShane has been muted.
Shane Ponraj
analystHi there. Morning to you. Am I coming through clearly?
Melinda McGrath
executiveAbsolutely.
Greg Horan
executiveCorrect.
Shane Ponraj
analystThanks, and I appreciate you taking my questions. First off, you said earlier that your goal is AUD 8 million in savings for fiscal 2027. Does the guidance also factor that in? Could you perhaps split that figure out by the main initiatives?
Melinda McGrath
executiveGreg, would you like to handle that question?
Greg Horan
executiveYeah. Shane, yes, that is part of what we've factored into the FY 2027 guidance. We'd expect those to keep compounding as we move into 2028 and past that. On how the initiatives break down, Matt, could you expand on that a bit more for me, please?
Matt Cordingley
executiveRight. We don’t really separate those initiatives into individual pieces. They originate from two sources. One source is operational efforts such as Lab of the Future, the consolidated Skin Lab project, the projects involving AI, OCR, and other automation efforts. The other source is the revenue initiatives that are highlighted in the presentation. We haven’t done so previously, and we don’t provide a piece-by-piece breakdown, but they are included in this year’s guidance, and they are expected to continue through FY 2028.
Shane Ponraj
analystThanks. And it's encouraging to learn that the yield for each GP appointment is going up. I'd be interested to know whether you're seeing yields rise in telehealth through digital referral systems, and how that stacks up against in-person appointments in the future?
Melinda McGrath
executiveTelehealth has stayed fairly level at roughly 20%, and it hasn’t shifted much since the post-COVID period, so we aren’t really seeing any meaningful change.
Shane Ponraj
analystAlright, thanks a lot. That's excellent.
Joe Geran
executiveOkay. Appreciate that, Shane. Our following question comes from Craig Wong-Pan. Craig, are you on the line?
Analyst
analystYes. First off, Melinda, I want to thank you for everything you've done to help us over the years, and I wish you all the best going forward.
Melinda McGrath
executiveAppreciate that, Craig.
Analyst
analystI'll start with a question about those sub-economic contracts and the AUD 14 million effect you recorded in FY 2026. Once it's annualized, how much of that will carry into FY 2027?
Melinda McGrath
executiveMatt, that one’s for you.
Matt Cordingley
executiveRegarding that annualized effect, Craig, it's going to be comparable to that figure, though not the entire AUD 14 million relates to contracts. Some of it comes from collection centers, and some from contracts we no longer hold. That split is factored into the 2027 guidance.
Analyst
analystAlright. Regarding consumables, we saw a solid result there. When I look at the cost-to-sales ratio, it came in at 16% during the second half, which is a fairly low percentage. I was hoping to get a clearer picture of what pushed it down, and can that kind of level hold up going into FY 2027?
Melinda McGrath
executiveSure, I’ll take that question. A lot of it comes down to the fact that we’re putting a very strong emphasis on managing contracts and managing inventory, so the team is doing a really solid job of pushing that price per test, if that’s how you want to describe it, lower, and also bringing usage down. On top of that, there’s a modest shift in mix that has had some effect too. But most of it reflects intentional procurement changes. It could fluctuate if respiratory and HPV rise, though revenue would rise as well in that case. So there would be a trade-off involving consumable costs versus the average fee going up. Matt, would you like to add anything there?
Matt Cordingley
executiveNo, I'd say that captures it well. We put a lot of effort into counterbalancing certain major contracts, and at this point we're examining essentially every category of spending we have influence over in order to push those costs even lower, Craig. As for whether this can hold up — your question — from where I sit, the answer is yes.
Analyst
analystAlright, thanks. This is our final question. Regarding depreciation along with interest expense during the second half, both rose somewhat. I just wanted to check whether those levels represent a solid run rate we ought to carry into FY 2027?
Matt Cordingley
executiveYes. Craig, AASB 16 D&A is going to come in somewhat higher in 2027. What happened is we had a large block of contracts with a single counterparty that renewed during the second half — with two counterparties, actually. All of those were reset at new rents, and that pushed up the AASB 16 balances. So that run rate will carry into 2027.
Analyst
analystAll right, thanks.
Joe Geran
executiveThe next person we have in the queue raising a hand is David Thilian.
Analyst
analystHello there. Good morning, Melinda, Greg, and Matt. I appreciate the chance to speak. I’d like to begin, I suppose, with the consumables piece. Obviously, you’ve achieved some reasonable savings there when compared with a year earlier. When I consider that in relation to revenue as a percentage, I heard what you said and the points you made about that being mostly the result of improved cost results from suppliers. I also want to, I guess, get a bit of an understanding of your billings initiatives. If I have this correct, much of the effort around billings is essentially about securing payment for tests for which you previously were not being paid. Shouldn’t that likewise be contributing to the consumables leverage?
Melinda McGrath
executiveMost likely, yes, that would probably be the case. Even so, we haven’t put a number on it, though it likely would be. The increases apply to testing not funded by Medicare or funded through health funds. That therefore covers contracts, health funds, and tests for which payment hasn’t come through, a smaller share right now, yet we expect it to grow. Yes, some benefit from that will be in there, but we haven’t quantified it.
Analyst
analystYeah, okay. I suppose what's somewhat connected here is simply getting a handle on how the business performed across that second half of 2026. When I look at your revenue and your EBIT results, you hit the low end of your revenue guidance, yet on the EBIT side you did really well. Thinking back to when you issued guidance around late February and how things actually trended by June, could you help us understand what shifted during those months versus what you had expected, please?
Melinda McGrath
executiveYeah. Look, the market is very slow. As I said, GP attendances are extremely, extremely slow. We expected that to keep going. It improved somewhat, though not by much. Most of the gain comes from the projects we've rolled out, and I believe we've captured part of that — we have a page covering it. Still, a fair number of projects will deliver a strong run rate going forward, which is why we're confident they'll continue to deliver improvement. On the efficiency side, we never run cost-cutting projects. All of them are sustainable process changes achieved through different thinking, automation, AI, offshoring, and altering how we operate. The revenue-related ones are difficult to reason through and difficult to program into the computer system, but we've accomplished that within the lab information system. They'll produce a run rate going forward too. On those, we're able to layer a price increase, something we truly haven't been in a position to do previously. We genuinely resolved to devote substantial effort here to try to gain control over a somewhat larger share of our revenue — pricing on our revenue.
Melinda McGrath
executiveWe're genuinely glad that began to deliver benefits during the final three months of the fiscal year. A key factor behind the guidance as it stands for 2027 is the substantial wage cost rises handed down by the Fair Work Commission. Matt, correct me if I'm wrong, but I believe it's 4.75 on the base rate alone, plus there's the gender undervaluation issue. There's a fairly significant standoff — unusual for this year — stemming from July the 1st that had to be addressed. Then as we move into the 2027 financial year, I think some of those projects will really begin accelerating. The run rate heading toward 2028 should look really strong, but you probably don't want to keep hearing that from me regarding 2027 and 2028. I'll hand things over to Greg.
Greg Horan
executiveThanks, Melinda. Yeah, I’d agree — when it comes to 2027 to 2028, we expect to see, and you can see it in the pipeline, that we have several initiatives that are going to land, especially Lab of the Future and National Skin Lab. The private billing that Melinda has been discussing will keep growing. From 2028 onwards, we’ll also get the advantage of some ability to raise prices on certain of those items. I think the pipeline we have in place positions us really well for continued margin expansion from 2028 and beyond.
Analyst
analystThanks a lot, Melinda. And thank you, Greg.
Joe Geran
executiveThank you. We have a couple of questions that came in writing. One is from Lyanne Harrison. Operating efficiencies. Congratulations on delivering material operational efficiencies against an inflationary backdrop. The FY 2027 guidance implies a 9%-9.5% EBIT margin, which is at the top end of the modest EBIT margin expansion vs FY 2026. Can you provide more color on margin expansion potential, including one, is strategic cost down initiatives becoming incrementally more difficult? And two, are you expected inflationary pressure to accelerate into FY 2027, particularly labor?
Melinda McGrath
executiveGreg, would you like to take that one?
Greg Horan
executiveYes. Thank you, Melinda. As we were just discussing, looking at the pipeline of initiatives, to repeat, Lab of the Future, National Skin Lab, and those billing improvement programs, which will flow directly to the bottom line. I wouldn't characterize it as though we have a strategic cost-out initiative problem or that it's getting progressively tougher. I believe we have a really strong pipeline and a proven track record. I think FY 2026 is a great benchmark for the business and shows just how resilient and disciplined the business has been. So on that front, I think we're looking quite good going forward.
Joe Geran
executiveThanks, Greg. We have another question coming in online from Ravine Cahundis. Could you expand a bit more on the AUD 13.4 million in labor FTE efficiencies that were achieved in FY 2026? How specifically are those cost reductions tied to the exited contract rather than to broader capacity decisions? And could you also give us any details about the providers that took over these contracts and how they might make them profitable — for instance, through greater local density or through pricing rationality?
Melinda McGrath
executiveI'll take the final question, and then Matt will handle the first one. That's a fair question, and my view is that no other party could make those contracts profitable — if they could, we would not have let them go. So on the FTE question, I'll pass things to Matt.
Matt Cordingley
executiveYeah. I think what you're really asking is how much those FTE cuts were tied specifically to the closures, versus other ways of bringing labor costs down across the business. The honest answer is that we examine every aspect of how efficiently this business runs, particularly on the labor side, and we leave nothing off the table. So those reductions weren't aimed specifically at the ACC closures. We view the ACCs holistically. We go through them on a regular basis throughout the year, and when one drops under our threshold, we then decide either to try to improve it or to retain it. Additional cost savings come from lab efficiency, and I highlighted that in the presentation when I talked about aligning labor hours with volume. So our workforce is flexible, and whether that means moving away from casual arrangements or balancing that casual mix so it's managed against volumes, that's the approach we take. We also run a shared services office located in Malaysia. We leverage it very efficiently to help control our labor costs too. It applies right across the board. Every area is targeted. That's the honest picture.
Joe Geran
executiveThanks, Matt. Just a couple of last questions here. Daniel Barone, when did the advantages from upfront billing first begin showing up in the P&L, and should we expect a more gradual benefit in FY 2027, or is that mostly baked into the base at this point?
Melinda McGrath
executiveGreg, would you like to take that question?
Greg Horan
executiveYeah. I'd say we're beginning to see some incremental benefit showing up in the FY 2027 P&L, and that benefit will keep growing through FY 2028 and beyond.
Joe Geran
executiveAbsolutely. Appreciate it, Greg. We’ll take the last question from Chris Richards. Although this isn’t material, could you share any update regarding how the veterinary laboratories are performing on PCP?
Greg Horan
executiveI'd say the veterinary business is doing well this year. Obviously, it has been part of the response to bird flu, so year-to-date we're seeing a slight uptick in volume for the vet business.
Joe Geran
executiveThanks, Greg. I believe we've been able to address the majority of your questions within the time available. Should you have any further questions you'd like to raise, kindly send them to us at investors@clinicallabs.com.au. That email address appears on our ASX releases, and we'll respond where it's appropriate to do so. Thank you, Greg, Melinda, and Matt, for your presentations, and thanks as well to our participants for joining and demonstrating such interest in ACL. We look forward to seeing you at our next investor webinar later this year. Goodbye.
Greg Horan
executiveI appreciate it.
Melinda McGrath
executiveI appreciate that.
Matt Cordingley
executiveI appreciate that.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Australian Clinical Labs Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Australian Clinical Labs Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Australian Clinical Labs Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.